|
|
|
| Discussion on the mechanism of Ligustri Lucidi Fructus in the treatment of liver cancer based on network pharmacology |
| ZHANG Fei1 LIU Jiemin2 ZHAO Qi3 |
1.Graduate School, Guizhou University of Traditional Chinese Medicine, Guizhou Province, Guiyang 550025, China;
2.Department of Digestive Endoscopy, Guizhou Provincial People’s Hospital, Guizhou Province, Guiyang 550002, China;
3.Department of Gastroenterology, the Second Affiliated Hospital of Guizhou University of Traditional Chinese Medicine, Guizhou Province, Guiyang 550003, China |
|
|
|
Abstract Objective To investigate the mechanism of Ligustri Lucidi Fructus in the treatment of liver cancer based on network pharmacology. Methods The compounds of Ligustri Lucidi Fructus were screened by traditional Chinese medicine systems pharmacology database and analysis platform, CNKI, Wanfang Medical Oline and PubMed. Target prediction was carried out in SwissTargetPrediction database, and “compound-target” network was constructed by Cytoscape software. The liver cancer targets were collected and intersected in Genecards, online Mendelian inheritance in man database to obtain the effective targets of Ligustri Lucidi Fructus in the treatment of liver cancer. Proteinprotein interaction (PPI) networks of effective targets of Ligustri Lucidi Fructus in the treatment of liver cancer were generated from the String database, and GO analysis and KEGG pathway enrichment analysis were performed in the Metascape database. Results There were ten kinds of effective chemical components and 134 targets of Ligustri Lucidi Fructus, 1033 targets of liver cancer were collected, and 47 targets of Ligustri Lucidi Fructus in the treatment of liver cancer were collected. The results of PPI network diagram showed that AKT1, ESR1 and EGFR were well associated with other proteins. GO analysis in Metascape database obtained 20 items most associated with disease, and KEGG pathway enrichment analysis obtained 14 pathways most associated with disease. Conclusion The mechanism of Ligustri Lucidi Fructus in the treatment of liver cancer is mainly through multi-target, multi-pathway and multi-pathway.
|
|
|
|
|
|
[1] Anwanwan D，Singh SK，Singh S，et al. Challenges in liver cancer and possible treatment approaches [J]. Biochim Biophys Acta Rev Cancer，2020，1873（1）：188314.
[2] 陈建国.肝癌的病因及预防研究新进展[J].肿瘤防治杂志，2003，10（11）：1121-1125.
[3] 熊雨.原发性肝癌中医理论及临床研究进展[D].重庆：重庆医科大学，2019.
[4] Lin WF，Lu JY，Cheng BB，et al. Progress in research on the effects of traditional Chinese medicine on the tumor microenvironment [J]. Integr Med，2017，15（4）：282-287.
[5] 胡兵，郑佳露，闫霞，等.女贞子对肝癌细胞全基因组表达谱影响[J].时珍国医国药，2017，28（4）：847-849.
[6] Zhou Y，Zhou B，Pache L，et al. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets [J]. Nat Commun，2019，10（1）：1523.
[7] 邱陈健，高静东.原发性肝癌阳虚质中医病机及治疗研究进展[J].亚太传统医药，2020，16（10）：196-198.
[8] 李剑霜，郑婷婷，金津津，等.徐斌治疗原发性肝癌常用药对经验介绍[J].新中医，2018，50（2）：185-187.
[9] 高福君.女贞子提取物抑制人肝癌细胞血管生长因子表达作用研究[J].中国实验方剂学杂志，2011，17（2）：139-142.
[10] 景明，李沛清，刘俊田，等.贞芪扶正分散片对肿瘤化疗的增效和减毒作用研究[J].时珍国医国药，2010，21（3）：604-605.
[11] 钟耀欣.解读《神农本草经》——女贞实[J].益寿宝典，2018（34）：40.
[12] 张忠泉，邢煜君，胡国强，等.β-谷甾醇诱导人肝癌HepG2细胞凋亡机制研究[J].中国中药杂志，2011，36（15）：2145-2148.
[13] 李聪，胡强，张燕翔，等.槲皮素的药理学活性研究进展[J].湖北中医杂志，2018，40（6）：63-66.
[14] 孙阳，于水澜，吴勃岩，等.槲皮素自微乳的抗肿瘤作用及其机制分析[J].中国实验方剂学杂志，2018，24（14）：97-101.
[15] 王铮华，梁统，李涛，等.山奈酚对人肝癌细胞Huh7生长及凋亡的影响[J].广东医学，2014，35（2）：192-194.
[16] 罗成，刘健康.羟基酪醇抗肿瘤机制研究进展[J].中国科学：生命科学，2014，44（1）：14-20.
[17] 田莉.AKT1、MDM2基因多态性与原发性肝癌的病例对照研究[D].乌鲁木齐：新疆医科大学，2016.
[18] 马体栋，赵凡，李碧香.慢病毒介导Akt1 shRNA载体转染对人肝母细胞瘤细胞株HepG2凋亡和增殖的影响[J].肿瘤药学，2019，9（4）：572-577.
[19] 窦橙云.ESR1基因甲基化在慢加急性乙型肝炎肝衰竭和HBV相关肝癌中的研究[D].济南：山东大学，2017.
[20] 朱冉旭，羊东晔，司徒伟基.EGFR的异常表达对于肝癌细胞增殖和侵袭能力的影响[J].黑龙江医药，2019， 32（4）：924-926.
[21] 朱礼慧.TRIM7通过直接靶向Src抑制肝细胞肝癌进展的作用效应与分子机制[D].济南：山东大学，2020.
[22] 王博龙.基于网络药理学的康莱特注射液3种主要成分抗肿瘤机制研究[J].中国现代应用药学，2019，36（1）：58-63.
[23] 高福君.女贞子提取物抑制人肝癌细胞血管生长因子表达作用研究[J].中国实验方剂学杂志，2011，17（2）：139-142.
[24] 杨金莲.酒精刺激激活NF-KB信号通路促进肝癌的生长和转移[D].合肥：安徽医科大学，2012.
[25] 陈红.NF-kB信号转导通路在H-ras12V转基因小鼠肝肿瘤发生中的作用[D].大庆：黑龙江八一农垦大学，2013. |
|
|
|
